Bottom line
Mounjaro and Zepbound are the same active drug — tirzepatide — manufactured by Eli Lilly in the same factory. The only meaningful differences are:
1. The FDA-approved indication on the label. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and obstructive sleep apnea in adults with obesity. 2. What insurance will pay for. Diabetes coverage is broad and well-established; obesity coverage is patchy and often excluded. 3. The price tag and savings programs. Cash prices and Lilly's savings card terms differ between the two brands.
Same molecule. Same dose ranges (2.5 mg through 15 mg weekly). Same injector pen design. Same side effect profile. Same effectiveness data — because the data was generated using the same drug.
Understanding the split between these two labels is the single most useful piece of GLP-1 literacy for anyone navigating insurance, pharmacy pricing, or a switch between conditions.
Why two names for the same drug
Pharmaceutical labeling in the U.S. is indication-specific. When Lilly first ran the SURPASS trials, tirzepatide was studied for type 2 diabetes and approved as Mounjaro in May 2022. The SURMOUNT trials studied the same molecule for chronic weight management in adults without diabetes. When those results read out, the FDA required a separate brand name and a separate labeled indication — that became Zepbound, approved in November 2023.
This isn't unique to tirzepatide. Semaglutide does the same thing:
- Ozempic — semaglutide, approved for type 2 diabetes
- Wegovy — semaglutide, approved for chronic weight management
- Rybelsus — oral semaglutide, approved for type 2 diabetes
The dual labels exist for three reasons: regulatory clarity (each trial population gets its own label), insurance routing (payers process diabetes and obesity claims differently), and commercial pricing (manufacturers can negotiate different rebates and run different patient assistance programs for each brand).
Are the doses really identical?
Yes. Both Mounjaro and Zepbound use the standard tirzepatide titration ladder:
- 2.5 mg weekly (starting dose, for tolerance only)
- 5 mg weekly
- 7.5 mg weekly
- 10 mg weekly
- 12.5 mg weekly
- 15 mg weekly (maximum)
The injector pens are functionally identical. The only visible differences are the brand label, the box design, and the prescribing information leaflet. A 5 mg Mounjaro pen and a 5 mg Zepbound pen are interchangeable from a clinical standpoint.
Pharmacists cannot legally substitute one for the other — they are separate NDC codes — but a prescriber can change the prescription with no clinical risk to the patient.
How insurance treats them differently
This is where the split actually matters. A typical commercial insurance formulary in 2026 looks something like:
Mounjaro (diabetes label):
- Covered with prior authorization on most major formularies
- Documentation needed: type 2 diabetes diagnosis, HbA1c
threshold (often ≥6.5% or ≥7%), prior trial of metformin
- Typical patient copay: $25–$100/month depending on plan tier
Zepbound (obesity label):
- Covered on roughly 30–45% of commercial formularies as of 2026
- Many plans explicitly exclude all anti-obesity medications
- Documentation needed: BMI ≥30, or BMI ≥27 with comorbidity,
prior weight loss attempt
- Typical patient copay when covered: $25–$200/month
If your insurance covers Mounjaro but excludes Zepbound, and you do not have type 2 diabetes, you cannot ethically or legally get Mounjaro prescribed to you for weight management. The diagnosis on the prior authorization must be accurate.
If you have both type 2 diabetes and obesity, your prescriber has a choice — and often Mounjaro will route through insurance more cleanly because diabetes drugs are universally covered.
How prices compare
Cash list prices for both drugs in 2026 are similar — roughly $1,000–$1,100 per month at the higher doses without any discounts. The savings programs differ:
Lilly's Mounjaro Savings Card is generally restricted to commercially-insured patients with type 2 diabetes, often bringing the copay to $25/month for those whose insurance covers the drug, or providing a smaller discount for those whose insurance does not.
Lilly's Zepbound Savings Card has had several iterations. The current version typically offers $25/month with insurance coverage, and a structured discount (around $349–$549 for a month's supply through Lilly's direct-to-consumer channel) for those without insurance coverage for obesity drugs.
[program:lillydirect]
Both savings programs exclude patients on Medicare, Medicaid, TRICARE, or other federal programs.
Switching from one to the other
A common scenario in 2026: a patient with both type 2 diabetes and obesity is on Mounjaro, the diabetes resolves (HbA1c drops into the normal range and stays there), and the prescriber considers continuing therapy under the Zepbound label.
Things to know about a switch:
- No dose change is needed. If you're stable on 10 mg
Mounjaro, you continue at 10 mg Zepbound.
- No washout is needed. It is the same drug.
- Insurance reauthorization is needed. Your prescriber will
submit a new prior authorization under the obesity indication. This may or may not be approved by your specific plan.
- Your savings card eligibility resets. You'll need to enroll
in the Zepbound savings program separately.
The reverse switch (Zepbound to Mounjaro) is also clinically straightforward but requires a confirmed type 2 diabetes diagnosis to be appropriate.
Compounded tirzepatide and the brand split
During the FDA-declared shortage of tirzepatide that ran through late 2024, compounding pharmacies legally produced tirzepatide-based formulations. The shortage was officially resolved in early 2025, and the FDA has since restricted the production of compounded tirzepatide to specific clinical exceptions (documented allergy to an excipient, specific dose not commercially available, etc.).
If you are currently on compounded tirzepatide in 2026, your prescriber should be transitioning you to brand-name Mounjaro or Zepbound based on your clinical indication. The compounded versions are not labeled as either brand — they're typically labeled by the active ingredient.
Common questions
If they're the same drug, can I split a Mounjaro prescription between weight loss and diabetes use? The drug works on both conditions simultaneously regardless of which label is on the box. The legal and insurance question is which indication the prescription was written for. If your prescriber documented diabetes and you also lose weight, that's expected — the SURPASS trials showed exactly that.
Will my employer's insurance ever start covering Zepbound? Coverage is expanding slowly. As of 2026, roughly 40% of large employers cover anti-obesity medications, up from about 25% in 2024. Self-insured employers (most large companies) make this decision plan-by-plan and sometimes mid-year.
Can I save money by buying Mounjaro in another country? Importing prescription medications into the U.S. for personal use is legally restricted and not something we recommend exploring. The savings are also smaller than they look once you account for cold-chain shipping and exchange rates.
Is one safer than the other? No. Identical molecule, identical safety profile, identical black-box warning (thyroid C-cell tumors based on rodent data, no human signal).
What this means for you
If you have type 2 diabetes: Mounjaro is your default brand and will route through insurance most easily.
If you have obesity without type 2 diabetes: Zepbound is the correct prescription, and your work is going to be on the insurance side — confirming coverage, navigating prior authorizations, and using the manufacturer's savings card if you qualify.
If you have both: your prescriber can choose, and the choice should be driven by which insurance pathway is cleanest for you.
The two-name system isn't a marketing trick — it's how the U.S. drug approval and payment systems work. Knowing the difference means you don't pay more than you have to, and you don't get denied for asking the wrong question.